Lexaria Bioscience (LEXX) EBIT Growth (1y) (2018 - 2026)
Lexaria Bioscience (LEXX) EBIT Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 8.32% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 19.82% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.20% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.14% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 269.85% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1,528.74% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -336.63% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 99.51% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -36.55% |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | 46.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 46.84% |
| Feb 28, 2026 | 47.22% |
| Nov 30, 2025 | 41.52% |
| Aug 31, 2025 | -22.04% |
| May 31, 2025 | -115.18% |
| Feb 28, 2025 | -311.83% |
| Nov 30, 2024 | -136.20% |
| Aug 31, 2024 | -97.74% |
| May 31, 2024 | 27.40% |
| Feb 29, 2024 | 49.53% |
| Nov 30, 2023 | 32.81% |
| Aug 31, 2023 | -48.84% |
| May 31, 2023 | 0.72% |
| Feb 28, 2023 | 8.63% |
| Nov 30, 2022 | 15.38% |
| Aug 31, 2022 | 42.54% |
| May 31, 2022 | 5.77% |
| Feb 28, 2022 | -31.16% |
| Nov 30, 2021 | -1,539.90% |
| Aug 31, 2021 | -50.99% |